(5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester is a pharmaceutical intermediate ingredient for Posaconazole is one of the newest triazole antifungal agents approved by the FDA for the prevention of invasive Aspergillus and Candida infections in immunocompromised patients. Such patients include haematopoietic stem cell transplant patients with graft-versus-host disease and patients with haematological malignancies undergoing chemotherapy.
